Trial Details

Not Recruiting
Basic Information
Clinical ID c3290
Identifier ACTRN12609000571279
Trial Title Prospective non controlled study of immunogenicity of Human Papilloma Virus (HPV) Vaccine in groups at special risk of poor vaccine result
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Special Risk Groups__1. Paediatric Rheumatalogical Disease__2. Inflammatory Bowel Disease__3. Acute Lymphoblastic Leukaemia__4. Solid Organ Transplant Recipients (kidney and liver)__5. Chronic Renal Disease__6. Bone Marrow Transsplant__The response to the HPV vaccine will be studied within these 6 special risk groups.; Special Risk Groups 1. Paediatric Rheumatalogical Disease 2. Inflammatory Bowel Disease 3. Acute Lymphoblastic Leukaemia 4. Solid Organ Transplant Recipients (kidney and liver) 5. Chronic Renal Disease 6. Bone Marrow Transsplant The response to the HPV vaccine will be studied within these 6 special risk groups.;Inflammatory and Immune System - Other inflammatory or immune system disorders
Interventions Licensed quadrivalent HPV vaccine. The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
Participant Information
Sponsor National Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation
City -
Country/Region Australia
Enrollment Criteria
Sex Requirement FEMALE
Age Requirement ADULT, CHILD, TEENAGER
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -